Ipca Laboratories has reported results for the year ended March 31, 2011.
The company has posted a net profit of Rs 255.37 crore for FY11, up by 22.08% as compared to Rs 209.19 crore in the last year. Total income has increased by 21.15% to Rs 1881.10 crore for the year under review from Rs 1552.74 crore in previous year.
On consolidated basis, the net profit has rose by 27.98% at Rs 262.82 crore for FY11 as compared to Rs 205.36 crore for FY10. Its total income has increased by 21.20% to Rs 1898.86 crore for the year under review from Rs 1566.76 crore a period ago.
Ipca Laboratories has recommended a final dividend of Rs 1.20 per share or 60% for the financial year ended March 31, 2011.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: